Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Innate Pharma (IPHA) FCF Margin (2019 - 2024)

Historic FCF Margin for Innate Pharma (IPHA) over the last 6 years, with Q4 2024 value amounting to 51.54%.

  • Innate Pharma's FCF Margin rose 105200.0% to 51.54% in Q4 2024 from the same period last year, while for Jun 2025 it was 51.09%, marking a year-over-year decrease of 509600.0%. This contributed to the annual value of 36.22% for FY2024, which is 171700.0% up from last year.
  • Latest data reveals that Innate Pharma reported FCF Margin of 51.54% as of Q4 2024, which was up 105200.0% from 62.06% recorded in Q4 2023.
  • In the past 5 years, Innate Pharma's FCF Margin ranged from a high of 2.41% in Q2 2022 and a low of 1297.25% during Q2 2020
  • Moreover, its 5-year median value for FCF Margin was 56.8% (2024), whereas its average is 250.7%.
  • Its FCF Margin has fluctuated over the past 5 years, first crashed by -3844000bps in 2021, then surged by 4749300bps in 2022.
  • Innate Pharma's FCF Margin (Quarter) stood at 90.57% in 2020, then tumbled by -424bps to 474.97% in 2021, then soared by 100bps to 0.04% in 2022, then plummeted by -165140bps to 62.06% in 2023, then increased by 17bps to 51.54% in 2024.
  • Its FCF Margin stands at 51.54% for Q4 2024, versus 62.06% for Q4 2023 and 31.56% for Q2 2023.